In clinical practice, a person diagnosed with type 2 diabetes who has a normal BMI with no features of metabolic syndrome is a good clue for the possible presence of autoantibodies and, potentially, a LADA diagnosis
When providers have biomarker and genetic context from the Precision Peptide Genetic Test, they can better discuss individual tolerance expectations, monitoring frequency, and potential dosing adjustments for GLP-1 medications when combined with testosterone replacement
In the experimental period, the low-dose groups (A2 and C) were administered 50 mg/kg l-carnitine via intraperitoneal injection once a day, and the high-dose groups (A3 and D) were given 100 mg/kg
134979-01-4, CH2COOH-PEG2-NH2.HCl References: [1] Kim JC, Park EJ, Na DH
Diarrhoea and vomiting can happen when taking GLP-1 agonists and might make the pill less effective